Company: SHPH
Filing Date: 2025-02-26
Form Type: 10-K
Source: 0001493152-25-008300
Chunk: 657

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-02-26
Form: 10-K
Item: Item 2
Chunk 657
---
 of Medicine of New Jersey and residency training from the Harvard Joint Center for Radiation Therapy.
His qualifications support his service as our Chief Executive Officer and Chairman of the Board of Directors.

Timothy
J. Lorber, CPA serves as the Company’s Chief Financial Officer, a position he assumed on a part-time basis commencing June
13, 2024 and assumed the full-time position of Chief Financial Officer on September 9, 2024. Mr. Lorber has more than 40 years of professional
finance experience, including Legg Mason, Inc. (“Legg Mason”), one of the world’s larger public global asset management
firms, where he worked from March 2006 to July 2020 serving in various finance leadership roles, including Managing Director and Chief
Accounting Officer until its sale in 2020. From August 2021 until June 2024, Mr. Lorber has served in leadership roles with several privately
held businesses, overseeing finance, technology and human resources functions. Prior to Legg Mason, Mr. Lorber served as Internal Audit
Director of Freddie Mac from August 2003 to March 2006 and has also worked for several international public accounting firms. Mr. Lorber
has extensive experience with mergers and acquisitions, valuations and complex accounting and financial reporting matters and holds a
Bachelor of Arts in Accounting from Loyola University, Maryland, and is a licensed CPA.

Michael
P. Vander Hoek serves as the Company’s Vice President, Operations and Regulatory, a position he has held since 2019, and served
as the Company’s Chief Financial Officer from 2019 until June 13, 2024. From November 2019 until April 2021, Mr. Vander Hoek served
as Director, Finance and Business Development at Georgetown Lombardi Comprehensive Cancer Center (“LCCC”), where he directed
a new five-year $221.9 million institutional commitment for cancer center research under a new NCI-approved cancer consortium arrangement
and recruited scientists to fulfill strategic objectives with senior leaders to improve cancer research and treatment. From 2007 until
November 2019, Mr. Vander Hoek served as Associate Director, Administration, at Georgetown’s LCCC, where he was responsible for
direct administrative operations for more than 400 faculty and staff in the department of oncology, radiation medicine, pathology and
biostatistics, bioinformatics and biomathematics, including managing $216.9 million in institutional commitments to LCCC from Medstar